Ignite Creation Date:
2024-05-06 @ 5:49 PM
Last Modification Date:
2024-10-26 @ 2:36 PM
Study NCT ID:
NCT05442190
Status:
RECRUITING
Last Update Posted:
2024-04-24
First Post:
2022-06-28
Brief Title:
Topical SGX302 for Mild-to-Moderate Psoriasis
Sponsor:
Soligenix
Organization:
Soligenix
Study Overview
Official Title:
Phase 2 Study Evaluating SGX302 Synthetic Hypericin in the Treatment of Mild-to-Moderate Psoriasis
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate SGX302 topical hypericin ointment with visible light in an initial 18-week treatment course for improving lesions in patients with mild-to-moderate psoriasis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None